New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
07:28 EDTABT, JNJ, LH, DHR, DGX, RHHBYCLFS review potential negative for Quest, LabCorp, says Piper Jaffray
Piper Jaffray views the Centers for Medicare & Medicaid Services' plan to revalue Clinical Lab Fee Schedule test codes as a potential negative for Quest Diagnostics (DGX) and LabCorp (LH) as well as diagnostic manufacturers like Abbott (ABT), Danaher (DHR), Johnson & Johnson (JNJ) and Roche (RHHBY). Piper says Quest and LabCorp both have around 12% of revenue exposure to CLFS, which it feels presents risk for additional reimbursement pressure in FY15. The review follows an Office of Inspector General report that found CMS paid between 18%-30% higher for 20 high volume/high expenditure tests than state and federal plans.
News For DGX;LH;ABT;DHR;JNJ;RHHBY From The Last 14 Days
Check below for free stories on DGX;LH;ABT;DHR;JNJ;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 17, 2014
06:04 EDTDHRDanaher reports Q2 EPS 95c, consensus 94c
Subscribe for More Information
July 16, 2014
16:05 EDTDHRDanaher to acquire Siemens Healthcare Diagnostics' clinical microbiology unit
Beckman Coulter, an indirect wholly-owned subsidiary of Danaher Corporation (DHR), announced that it has entered into a definitive agreement to purchase the clinical microbiology business of Siemens Healthcare Diagnostics (SIEGY). The microbiology business operates with an installed base of over 6,000 instruments globally. The transaction is expected to close in 1Q15.
15:27 EDTDHRNotable companies reporting before tomorrow's open
Subscribe for More Information
14:01 EDTDHRDanaher technical comments before earnings
Subscribe for More Information
11:23 EDTRHHBYRoche Alzheimer drug shows mixed results in trial, NYT says
Subscribe for More Information
10:36 EDTABTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
09:25 EDTABTAbbott expects Global Nutrition sales to return to double digit growth in 2H14
Subscribe for More Information
09:23 EDTABTOn The Fly: Pre-market Movers
HIGHER: Time Warner (TWX), up 15% after company confirmed that it rejected an $80B takeover offer from 21st Century Fox (FOX, FOXA), as had been reported earlier this morning... Apple (AAPL), up 2% after announcing an enterprise mobile partnership with IBM (IBM), which is also up 2%... International Game (IGT), up 9.5% after agreeing to be acquired by GTECH for $4.7B in cash and stock... FireEye (FEYE), up 5% after shares upgraded at Goldman... Precision Drilling (PDS), up 4% after announcing strategic agreement with Schlumberger (SLB), upgraded at Deutsche Bank... Mellanox (MLNX), up 4.7% following upgrade at Jefferies. UP AFTER EARNINGS: Intel (INTC), up 5.4%... HCA Holdings (HCA), up 6%... Textron (TXT), up 3.2%... Abbott (ABT), up 1%. DOWN AFTER EARNINGS: PNC Financial (PNC), down 2.5%... MGIC Investment (MTG), down 3.6%. LOWER: Yahoo (YHOO), down 3% after downgraded at CRT Capital following second quarter earnings report... Ares Capital (ARCC), down 2.5% after filing to sell 11.85M shares of common stock... Nationstar (NSM), down 2.4% after downgraded at Wells Fargo... Walter Investment (WAC), which was also downgraded at Wells Fargo, down 1.6%.
09:17 EDTABTAbbott sees Q3 ongoing EPS 59c-61c, consensus 60c
Sees Q3 revenue growth in mid-single digits, consensus $5.63B. Expects neutral impact from foreign exchange.
09:16 EDTABTAbbott sees FY14 revenue growth in mid single digits, consensus $22.42B
Subscribe for More Information
09:03 EDTABTSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
08:55 EDTJNJJohnson & Johnson pullback a buying opportunity, says Leerink
Leerink views the post-earnings pullback in shares of Johnson & Johnson as a buying opportunity. The firm expects "several" more quarters of outperformance and raised its price target for the stock to $115 from $110. It keeps an Outperform rating on J&J.
08:16 EDTABTLew's letter could bring 'chilly' tax inversion environment, says BMO Capital
Subscribe for More Information
07:59 EDTABTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:49 EDTABTAbbott reports Q2 Nutrition sales $1.73B; Reports Q2 Diagnostics sales $1.19B
Subscribe for More Information
07:47 EDTABTAbbott says it's on track for sales growth acceleration in 2H14
Subscribe for More Information
07:46 EDTABTAbbott raises FY14 ongoing EPS to $2.19-$2.29 from $2.16-$2.26, consensus $2.19
07:46 EDTABTAbbott reports Q2 ongoing EPS 54c, consenus 51c
Subscribe for More Information
07:25 EDTJNJJohnson & Johnson should be bought on pullbacks, says RBC Capital
RBC Capital believes that Johnson & Johnson reported strong Q2 results, and the company raised its estimates for the company. The firm continues to recommend buying the stock on pullbacks.
06:26 EDTRHHBYBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use